In this episode of Hospital Medicine Unplugged, we sprint through delirium tremens—the most dangerous stage of alcohol withdrawal—recognize the neurochemical storm, identify high-risk patients, and treat aggressively with benzodiazepines and supportive care to prevent fatal complications.

We begin with epidemiology and why DTs matter. Delirium tremens occurs in 3–5% of hospitalized patients with alcohol withdrawal and represents the most severe manifestation of the withdrawal spectrum. The syndrome combines acute delirium—rapidly fluctuating attention and cognition—with severe autonomic hyperactivity. Historically mortality approached 15%, but with modern aggressive treatment it has fallen to about 1–4%. When death occurs, it is usually due to hyperthermia, malignant arrhythmias, withdrawal seizures, or underlying medical illness.

Next comes the neurobiology driving withdrawal. Chronic alcohol exposure forces the brain to compensate for alcohol’s depressant effects. Over time:

• NMDA glutamate receptors are upregulated

While alcohol is present, its GABA-enhancing and NMDA-suppressing effects maintain balance. When alcohol is abruptly stopped, that balance collapses. The result is unopposed excitatory neurotransmission, increased glutamate signaling, reduced GABA inhibition, and massive central nervous system hyperexcitability. Additional contributors include increased norepinephrine activity, dopaminergic alterations, and calcium-mediated excitotoxicity, producing the agitation, tremor, and seizure risk characteristic of severe withdrawal.

Risk stratification is essential because not every patient with withdrawal develops delirium tremens. The strongest predictor is a prior history of DTs, which carries a likelihood ratio of roughly 2.9 for recurrence. Other important risk factors include:

• Recent withdrawal seizures, especially multiple seizures

Another key concept is the kindling effect. Repeated withdrawal episodes progressively sensitize neuronal circuits, meaning each withdrawal episode tends to become more severe than the last.

The timeline of alcohol withdrawal follows a predictable pattern.

• 6–12 hours: early withdrawal—tremor, anxiety, tachycardia

Importantly, about one-third of untreated withdrawal seizures progress to delirium tremens, making early treatment critical.

Clinically, DTs presents with severe agitation and delirium combined with autonomic instability. Key features include:

• Fluctuating confusion and disorientation

Diagnosis is clinical—delirium occurring in the context of alcohol withdrawal. The CIWA-Ar scale helps quantify withdrawal severity, but it becomes less reliable once patients develop delirium because it depends on patient responses. In ICU settings, clinicians often switch to CAM-ICU, RASS, MINDS, or DDS scales.

Laboratory evaluation should focus on complications and reversible triggers. Important tests include:

• Electrolytes (magnesium, potassium, phosphate)

Neuroimaging should be obtained if the presentation is atypical or focal neurologic deficits are present.

Management centers on rapid sedation and physiologic stabilization.

Benzodiazepines are first-line therapy, acting as GABA-A agonists to counter the hyperexcitable brain. Two dosing strategies dominate:

• Symptom-triggered therapy, which reduces medication exposure and treatment duration

Clinicians should not fear very high benzodiazepine doses. Severe DTs may require hundreds of milligrams of diazepam per day, and case reports describe successful treatment with 260–480 mg/day.

Agent selection depends on clinical context:

• Diazepam or chlordiazepoxide – preferred long-acting agents for front-loading

For benzodiazepine-refractory DTs, ICU-level therapies may be required.

Adjunctive options include:

• Phenobarbital, which enhances GABA signaling and may reduce mechanical ventilation risk

Antipsychotics should never be used as monotherapy, as they lower seizure threshold. They may be used only as adjuncts for severe hallucinations or agitation.

Supportive care is equally critical. One rule must never be forgotten:

Thiamine must be administered before glucose.

High-dose thiamine—500 mg IV once or twice daily for several days—prevents Wernicke encephalopathy, a devastating but preventable neurologic complication.

Other essential measures include:

• IV fluids and hydration

Patients should be admitted to the ICU when they develop delirium tremens, severe withdrawal (CIWA ≥20), refractory symptoms despite benzodiazepines, unstable vital signs, or serious comorbid illness such as pancreatitis or GI bleeding.

Complications of DTs can be dramatic and life-threatening. They include:

• Cardiac arrhythmias and myocardial ischemia

Despite modern treatment, patients who experience DTs have significantly increased long-term mortality, with an annual mortality rate around 8%, particularly due to trauma, suicide, and other alcohol-related causes.

We close with the essential clinical pearls:

• Delirium tremens is a clinical diagnosis—treat immediately

Recognize the timeline, treat early, and sedate aggressively—because in delirium tremens, rapid intervention transforms a historically lethal syndrome into a manageable medical emergency.

In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors.

We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50.

The key classification hinges on duration.

Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines.

Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms.

Two major autoimmune endotypes exist:

Type I autoimmune (autoallergic) CSU

Type IIb autoimmune CSU

These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies.

Diagnosis is largely clinical but follows the “7C” framework:

Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include:

Certain red flags should trigger referral or further evaluation:

To measure disease activity, clinicians rely on validated tools.

The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42.

Interpretation:

The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while <12 suggests poorly controlled disease.

Management follows a stepwise escalation strategy.

Step 1: Second-generation H1 antihistamines

Step 2: Dose escalation

Step 3: Omalizumab

Patients with incomplete response may require higher doses or shorter dosing intervals.

Step 4: Cyclosporine

Short courses of systemic corticosteroids (20–50 mg/day for <10 days) may help during severe flares but should never be used long-term.

The treatment landscape is expanding rapidly.

Two newly approved therapies include:

Dupilumab

Remibrutinib

Another critical diagnostic consideration is urticarial vasculitis, which can mimic CSU but requires a different approach.

Key distinguishing features include:

Systemic symptoms such as fever, arthralgia, or eye inflammation further increase suspicion. Diagnosis is confirmed by skin biopsy showing leukocytoclastic vasculitis.

Finally, we talk prognosis. Chronic spontaneous urticaria is often self-limited but unpredictable.

Remission rates:

Average disease duration is 1–4 years, though relapse occurs in up to one-third of patients.

We close with the key clinical pearls:

• Chronic urticaria is rarely allergic—most cases involve autoimmune mast-cell activation

Recognize the pattern, escalate therapy systematically, and remember—modern immunologic therapies are transforming outcomes for patients with chronic urticaria.

In this episode of Hospital Medicine Unplugged, we sprint through acute exacerbation of interstitial lung disease (AE-ILD)—recognize the sudden decline, rule out infection and cardiac causes, support oxygenation, and navigate a disease with limited treatment options and high mortality.

We begin with the diagnostic framework defined by the 2016 International Working Group. Acute exacerbation is characterized by rapid respiratory deterioration within about 1 month, accompanied by new bilateral ground-glass opacities or consolidation on CT superimposed on pre-existing fibrotic lung disease, with no evidence of cardiac failure or fluid overload. Importantly, this definition now applies across fibrosing interstitial lung diseases, not just idiopathic pulmonary fibrosis (IPF).

The critical bedside principle: AE-ILD is a diagnosis of exclusion. Infection, pulmonary embolism, pneumothorax, and heart failure must be aggressively ruled out because they can mimic exacerbations and require completely different management.

Next, we turn to pathobiology and why these patients deteriorate so rapidly. Acute exacerbations often represent diffuse alveolar damage superimposed on chronic fibrosis, producing a clinical picture similar to ARDS. However, in some non-IPF ILDs, organizing pneumonia patterns are more common—one reason those patients may respond better to immunosuppressive therapy.

Treatment remains challenging because no therapy has definitively proven benefit in randomized trials. Corticosteroids remain the most widely used intervention, but evidence is mixed.

Recent data suggest a key difference between ILD subtypes. In non-IPF ILD, higher-dose corticosteroids (>1 mg/kg prednisone equivalent) have been associated with improved survival and lower 90-day mortality. Early tapering—reducing doses by more than 10% within the first two weeks—may further improve outcomes.

In contrast, IPF exacerbations respond less predictably, and some studies suggest high-dose steroids may increase mortality, likely because the underlying pathology is often diffuse alveolar damage rather than steroid-responsive inflammation.

One therapy that should not be used is cyclophosphamide combined with steroids, which has been shown to increase mortality in acute exacerbations of IPF.

Respiratory support becomes the next critical decision point. Many patients develop severe hypoxemic respiratory failure, but outcomes with invasive mechanical ventilation are poor.

Across multiple studies:

Ventilator management therefore focuses on lung-protective strategies, similar to ARDS care:

• Low tidal volumes

Because survival after intubation is so limited, early discussions about goals of care are essential. Noninvasive ventilation or high-flow nasal oxygen may be appropriate for selected patients who decline intubation.

Prevention is therefore critically important. Antifibrotic therapies have significantly reduced exacerbation risk in IPF.

Two major agents are used:

• Nintedanib – shown in the INPULSIS trials to reduce the risk of acute exacerbations

Meta-analyses show antifibrotics reduce the risk of acute exacerbations by roughly 37%, and nintedanib has also been approved for progressive fibrosing ILDs beyond IPF, after the INBUILD trial demonstrated substantial slowing of lung function decline.

New therapies are also emerging. The FIBRONEER-ILD trial studied nerandomilast, a novel PDE-4 inhibitor, and although the composite endpoint did not reach statistical significance, the study demonstrated a meaningful reduction in mortality, suggesting a potential future role in progressive pulmonary fibrosis.

Another key strategy is early referral for lung transplantation, particularly in patients with progressive fibrotic disease. Acute exacerbations can occur unpredictably and often represent a terminal event in advanced ILD, making transplant evaluation crucial before severe deterioration occurs.

We close with the key system moves for inpatient teams:

• Recognize sudden respiratory decline in patients with fibrotic lung disease

Acute exacerbation of ILD remains one of the most devastating events in pulmonary medicine—but early recognition, careful supportive care, and preventive antifibrotic therapy can meaningfully improve outcomes.

In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in.

We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes.

The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury.

Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses.

Three effective options:

The biggest real-world mistake isn’t drug choice—it’s delay and underdosing.

If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice.

The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients.

Recommended doses:

Because efficacy is equivalent, patient factors guide the choice:

Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used.

When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring.

Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity:

• Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use

Most modern practice favors propofol or midazolam over barbiturate coma.

A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease.

If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%.

Management expands to include:

Two particularly challenging syndromes fall into this category:

Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome.

Prognosis varies dramatically depending on response to therapy:

Poor outcomes are associated with older age, acute symptomatic etiologies (stroke, infection, hypoxic injury), prolonged seizures, and nonconvulsive status epilepticus with coma, which is one of the strongest predictors of mortality.

Finally, systems matter. Hospitals that implement structured status epilepticus protocols dramatically improve outcomes. Protocol adherence reduces time to second-line therapy from nearly an hour to about 20 minutes and lowers ICU transfer rates.

We close with the practical escalation algorithm every inpatient team should know:

• 0–5 minutes: ABCs, glucose check, IV access, prepare meds

Treat fast, escalate early, follow the algorithm, and search relentlessly for the underlying cause. In status epilepticus, every minute of uncontrolled seizure activity threatens the brain.

In this episode of Hospital Medicine Unplugged, we sprint through measles—one of the most contagious infectious diseases known—covering transmission, classic clinical presentation, complications, diagnosis, and prevention through vaccination.

We start with the big picture. Measles (rubeola) is a highly contagious viral illness caused by a paramyxovirus and remains a major global public health concern despite the availability of an effective vaccine. Clinically, the disease is defined by fever, cough, coryza, conjunctivitis, and a characteristic maculopapular rash.

After decades of progress toward elimination, measles has resurged worldwide. Global cases increased dramatically from about 132,000 cases in 2016 to nearly 870,000 in 2019, driven by large outbreaks and declining vaccination coverage. Pandemic-related disruptions to immunization programs worsened the problem, with global first-dose vaccine coverage dropping to 81% in 2021—the lowest level in more than a decade. Even in the United States, outbreaks continue to occur, with the vast majority of cases seen in unvaccinated individuals or those with unknown vaccination status.

The reason measles spreads so easily is its extraordinary transmissibility. The virus spreads through airborne respiratory droplets, and viral particles can remain suspended in the air for up to two hours after an infected person leaves the area. The basic reproduction number (R₀) is estimated at 12–18, meaning a single infected person can transmit the virus to more than a dozen susceptible individuals.

The incubation period is typically 10–14 days, and patients become contagious about four days before the rash appears and remain infectious until four days after rash onset. Because measles spreads so efficiently, achieving herd immunity requires at least 95% vaccine coverage with two doses.

Clinically, measles follows a predictable three-phase course.

First is the prodromal phase, lasting about 2–4 days. Patients develop high fever along with the “three Cs”: cough, coryza, and conjunctivitis. A key diagnostic clue during this phase is the appearance of Koplik spots—small bluish-white lesions on the buccal mucosa, which are considered pathognomonic and typically appear 1–2 days before the rash.

Next comes the exanthem phase, when the classic erythematous maculopapular rash appears. The rash begins on the face and hairline, then spreads downward to the trunk and extremities over several days. It often becomes confluent on the face and upper body before gradually fading in the same order that it appeared.

The final stage is the convalescent phase, during which symptoms gradually resolve, typically within about one week after rash onset in uncomplicated cases.

Despite this classic presentation, measles is far from benign. Approximately 30–40% of patients develop complications, particularly among infants, adults, pregnant individuals, immunocompromised patients, and malnourished children.

Common complications include:

More severe complications involve the central nervous system. Acute postinfectious encephalitis occurs in roughly 1 in 1,000 cases and carries a 20% mortality rate. Immunocompromised patients may develop measles inclusion-body encephalitis, which is nearly always fatal.

One of the most devastating complications is subacute sclerosing panencephalitis (SSPE)—a progressive degenerative brain disease that develops 7–10 years after infection. Although rare, it is universally fatal within several years of onset.

Measles also produces a phenomenon known as immune amnesia. The virus suppresses immune memory for 2–3 years, increasing vulnerability to other infections and contributing to excess mortality even after recovery from the acute illness.

Diagnosis is often suspected clinically when patients present with fever, rash, and the three Cs, especially if Koplik spots are observed. However, laboratory confirmation is essential—particularly during outbreaks or in previously vaccinated individuals who may develop modified measles with milder symptoms.

Diagnostic testing includes:

Management of measles is primarily supportive, as no specific antiviral therapy exists. Treatment focuses on hydration, fever control, nutritional support, and treatment of secondary bacterial infections.

One intervention with strong evidence is vitamin A supplementation. Clinical trials have demonstrated that vitamin A significantly reduces measles-related mortality, particularly in children. Current recommendations are to administer two age-adjusted doses of vitamin A on consecutive days, with an additional dose given later if vitamin A deficiency is suspected.

Ultimately, the most effective strategy against measles is prevention through vaccination. The MMR vaccine provides highly effective protection, with two doses achieving approximately 97% immunity.

We close with the key clinical takeaways:

• Measles is among the most contagious infectious diseases known

Measles is often viewed as a childhood disease of the past—but as vaccination rates decline in some regions, clinicians must remain vigilant. Recognizing measles quickly, isolating cases, and promoting vaccination remain essential tools for preventing outbreaks and protecting vulnerable populations.

In this episode of Hospital Medicine Unplugged, we sprint through aplastic anemia—recognize the pancytopenia, confirm marrow failure, suppress the immune attack, and watch for clonal evolution.

We open with the diagnostic framework that defines disease severity. The Camitta criteria remain the standard classification. Severe aplastic anemia requires bone marrow cellularity <25% plus at least two of three cytopenias:

Very severe disease is defined by ANC <200/μL, a group at extremely high infection risk. These criteria matter because treatment decisions hinge on severity, patient age, and donor availability.

Next, we unpack the pathophysiology—the immune system attacking hematopoiesis. In acquired aplastic anemia, cytotoxic T cells target hematopoietic stem and progenitor cells (HSPCs). These T cells release interferon-γ and TNF-α, which activate Fas/Fas-ligand pathways, triggering apoptosis of stem cells and collapsing bone marrow production.

Recent discoveries explain how immune escape and clonal selection occur. IFN-γ suppresses HSPCs expressing HLA class I molecules, while HLA-deficient clones evade immune destruction, creating a survival advantage in about 30% of patients. Meanwhile, regulatory T cells are decreased, and their restoration often parallels hematologic recovery.

Then comes one of the biggest therapeutic advances in decades: adding eltrombopag to immunosuppressive therapy. Standard treatment has long been horse antithymocyte globulin (ATG) plus cyclosporine, but the RACE trial changed the landscape.

When eltrombopag was added:

Because of these results, ASH 2025 guidelines now recommend eltrombopag alongside ATG and cyclosporine for severe and very severe aplastic anemia in both adults and children. Beyond thrombopoiesis, eltrombopag appears to stimulate stem-cell recovery and counteract IFN-γ–mediated suppression.

For curative therapy, we turn to hematopoietic stem cell transplantation. Modern guidelines use age-based decision pathways:

• <20 years: matched sibling transplant or immunosuppressive therapy

Haploidentical transplant is generally reserved for later lines, with immunosuppressive therapy favored initially.

Another hallmark of aplastic anemia is its relationship with paroxysmal nocturnal hemoglobinuria (PNH). Up to 50% of patients harbor a PNH clone, detectable by FLAER-based flow cytometry with CD55/CD59 testing. Importantly, the presence of a PNH clone is actually a favorable prognostic sign.

Patients with PNH clones show:

The mechanism is elegant: GPI-negative stem cells with PIGA mutations escape immune destruction, allowing them to survive when normal HSPCs are targeted.

Despite improved survival, long-term complications remain a major concern. About 10–20% of patients develop clonal evolution to myelodysplastic syndrome or acute myeloid leukemia within 10 years, particularly after immunosuppressive therapy.

Genomic studies show clonal hematopoiesis in roughly half of patients, with mutation patterns predicting outcomes:

Risk factors for clonal evolution include older age, poor response to immunosuppressive therapy, high-risk mutations, and multiple mutations with higher allele burden.

When secondary myeloid malignancies occur, they often carry high-risk cytogenetics such as monosomy 7 or complex karyotypes, with ~40% five-year survival without transplant. Fortunately, allogeneic stem cell transplantation can improve survival to about 64%.

The big picture today is far more optimistic than in the past. With modern therapy—including ATG, cyclosporine, and eltrombopag—five-year survival now exceeds 80%, with some studies reporting survival approaching 97%. But relapse still occurs in about 22% of patients, making long-term monitoring essential.

We close with the system moves: confirm severe disease using Camitta criteria, suppress the immune attack with ATG + cyclosporine + eltrombopag, evaluate for transplant based on age and donor availability, screen all patients for PNH clones, and monitor closely for clonal evolution.

Aplastic anemia is no longer uniformly fatal—but recognizing the immune mechanism, treating early, and tracking clonal risk can transform outcomes for these patients.

In this episode of Hospital Medicine Unplugged, we sprint through Brugada syndrome—spot the ECG, stratify the risk, prevent sudden cardiac death, and avoid the triggers that unmask malignant arrhythmias.

We start with the ECG that makes the diagnosis. Type 1 Brugada pattern is the only diagnostic finding: coved ST elevation ≥2 mm in ≥1 right precordial lead (V1–V3) followed by a negative T wave. The 2013 consensus simplified the diagnosis—a Type 1 pattern alone (spontaneous or drug-induced) is sufficient, without requiring symptoms or family history. Type 2 (“saddleback”) pattern shows ≥0.5 mm ST elevation with a convex ST segment and positive T wave, but it is only suggestive, not diagnostic.

Next comes a critical inpatient pearl: Brugada ECG patterns are dynamic. They may appear and disappear and are often unmasked by fever, sodium-channel blockers, increased vagal tone, or post-prandial states. This is why hospitalized patients with unexplained syncope or fever should have careful ECG review—the pattern may only be visible transiently.

Risk stratification drives management and ICD decisions, which is one of the hardest parts of Brugada care.

High-risk patients (Class I indication for ICD):

These patients face annual event rates of roughly 5–10%, making ICD therapy life-saving.

Intermediate risk:

Low risk (ICD not indicated):

A key myth to bust: family history alone does NOT reliably predict individual arrhythmic risk.

We also review BRUGADA-RISK, a modern clinical risk model incorporating ECG and clinical variables to estimate 5-year arrhythmic risk, showing strong predictive performance with ~71% sensitivity and ~80% specificity at a 10% risk threshold.

Then comes the debate over electrophysiology studies (EPS). Current guidelines give Class IIb support for programmed ventricular stimulation in asymptomatic patients with spontaneous Type 1 ECG. Inducible arrhythmias roughly double the risk of events, but the absence of inducibility does not guarantee safety, so clinical history still matters most.

When prevention matters most, remember the bottom line: ICD implantation is the only proven therapy that prevents sudden cardiac death in Brugada syndrome.

Class I indications for ICD:

For patients with recurrent ICD shocks, escalation strategies include quinidine therapy or catheter ablation targeting abnormal epicardial substrate in the RV outflow tract.

Hospital teams must also know the medications that worsen Brugada. Drugs that block cardiac sodium channels can unmask the ECG pattern and trigger ventricular arrhythmias. High-risk categories include Class IC antiarrhythmics (flecainide, propafenone), tricyclic antidepressants, lithium, certain antipsychotics, local anesthetics like bupivacaine, propofol, cocaine, and excessive alcohol. The safest move is to check brugadadrugs.org before prescribing.

Finally, one of the most important bedside pearls: fever is a powerful arrhythmic trigger in Brugada syndrome. Temperature-dependent sodium channel dysfunction can convert a silent patient into a ventricular arrhythmia emergency. That’s why aggressive antipyretic therapy is mandatory in any febrile Brugada patient—especially in children and hospitalized patients.

We close with the take-home system moves: recognize the Type 1 ECG pattern, treat fever aggressively, avoid sodium-channel-blocking medications, risk-stratify carefully, and implant ICDs in the right patients.

Brugada syndrome may hide in plain sight—but once you know the ECG and the triggers, you can identify risk early and prevent sudden cardiac death.

In this episode of Hospital Medicine Unplugged, we tackle one of the most ethically charged and clinically challenging topics in inpatient care: the use of restraints in the hospital setting. When are restraints justified, why do we still use them so often, and what does the evidence actually show about benefit versus harm?

We start by defining physical restraints—any device or method that limits a patient’s movement, from wrist and ankle restraints to vests, belts, bed rails, and enclosure beds—and chemical restraints, medications used primarily to control behavior rather than treat an underlying condition. We unpack why experts increasingly reject the term “chemical restraint,” emphasizing pharmacologic treatment of agitation aimed at calming, not sedating, patients while addressing root causes.

Next, we explore why restraints are used: fall prevention, prevention of device removal, management of delirium or agitation, and protection of staff. But here’s the paradox—observational data consistently show higher rates of the very outcomes restraints are meant to prevent, including unplanned extubations, device removal, increased agitation, delirium, and longer ICU stays.

We break down the scope of the problem. Nearly 1 in 10 hospitalized patients experiences restraint use, with rates approaching 40% of ICU encounters and even higher among mechanically ventilated patients. Use varies widely by setting, staffing, and culture—highlighting that restraint use is often system-driven, not patient-driven.

The heart of the episode focuses on ethics and law. Restraints represent a profound restriction of liberty, and ethical use requires three conditions: medical appropriateness, informed consent (or a valid emergency exception), and use of the least restrictive option. We review federal regulatory requirements—restraints only for imminent harm, after less restrictive measures fail, time-limited orders, mandatory face-to-face evaluations, continuous monitoring, and early removal.

We then confront the real harms. Physically: DVT, PE, aspiration pneumonia, fractures, pressure injuries, rhabdomyolysis, asphyxiation, and death. Psychologically: fear, loss of dignity, and PTSD, affecting up to 25–47% of patients after a restraint event. These risks rise with each additional day of restraint use.

From there, we pivot to what actually works: alternatives. Multicomponent, non-pharmacologic strategies—reorientation, sleep hygiene, pain control, early mobility, family engagement, sitters, sensory optimization, and delirium prevention bundles like ABCDEF—reduce delirium and restraint use by 40–60% while improving outcomes.

We close with practical takeaways: assess underlying causes first (pain, hypoxia, infection, withdrawal, delirium), use verbal de-escalation and environment before meds, reserve restraints for true emergencies, document meticulously, reassess relentlessly, and remove early. The bottom line: restraints are not benign, not preventive, and not routine care—they are a last resort in modern, patient-centered hospital medicine.

Fast, evidence-driven, and ethically grounded—protect safety without sacrificing dignity.

In this episode of Hospital Medicine Unplugged, we tackle dementia with behavioral and psychological symptoms (BPSD) in the hospitalized patient—why it happens, how to assess it fast, and how to manage it safely without making things worse.

We start with the big picture: BPSD affects >90% of people with dementia, often driving hospital admissions. Symptoms span agitation, aggression, psychosis, depression, anxiety, apathy, sleep disturbance, and disinhibition—and they’re not benign. In the hospital, BPSD is linked to longer stays, higher mortality, restraint use, staff injury, early institutionalization, and one-third of total dementia care costs.

Next, we walk through the do-first inpatient assessment. Rule out delirium (acute onset, fluctuating attention), then hunt for reversible triggers: pain, constipation, urinary retention, infection, hypoxia, metabolic derangements, sleep disruption, and iatrogenic harm from polypharmacy—especially anticholinergics, benzodiazepines, and opioids. Collateral history is critical to establish baseline behavior. Use structured tools like CAM/4AT for delirium, PAINAD for nonverbal pain, and NPI or CMAI to quantify symptoms. The DICE approach (Describe–Investigate–Create–Evaluate) keeps management personalized and efficient.

We emphasize that non-pharmacologic strategies are first-line—always. In the hospital, this means person-centered care: reorientation, sleep hygiene, early mobility, sensory optimization (glasses/hearing aids), hydration, toileting, nutrition, and calm communication. Caregiver- and staff-focused interventions have the strongest evidence, reducing both symptom burden and distress. Music therapy, tailored activities, exercise, massage/touch, and multicomponent delirium programs like HELP can meaningfully reduce agitation and prevent escalation.

When symptoms threaten safety, we cover how to use meds sparingly and smartly. Before adding anything, do a medication cleanup. Pharmacotherapy is time-limited, lowest dose, shortest duration, and always paired with non-drug strategies.

We close with hospital pearls: no routine drugs for delirium; antipsychotics only for dangerous behaviors refractory to non-drug care. Plan early for deprescribing—one-third of patients started on antipsychotics in the hospital leave on them unless you stop it. At discharge, communicate what worked: triggers, de-escalation strategies, sleep plans, toileting schedules, and a clear reassessment plan. Align care with goals, dignity, and function.

Bottom line: Treat the cause, lead with non-pharmacologic care, reserve meds for safety, reassess relentlessly, and deprescribe early.

In this episode of Hospital Medicine Unplugged, we tackle one of the most anxiety-provoking inpatient consults: acute facial weakness—Bell’s palsy or stroke? We break down how to tell them apart fast, why the distinction matters, and how to manage each safely in hospitalized patients.

We start with the bedside exam that saves lives. Forehead involvement = peripheral (Bell’s palsy); forehead sparing = central (stroke)—until proven otherwise. Bell’s palsy presents with acute unilateral facial paralysis involving the forehead, often peaking within 72 hours, and may include post-auricular pain, altered taste, hyperacusis, or dry eye, without other neurologic deficits. Stroke typically hits suddenly, often spares the forehead, and comes with red flags like limb weakness, aphasia, gaze deviation, dysphagia, or altered mental status.

We walk through the don’t-miss pitfalls: brainstem strokes that mimic a lower motor neuron pattern, bilateral facial weakness, gradual or progressive onset, recurrent ipsilateral palsy, hearing loss or vertigo, and facial palsy in post-op, ICU, immunocompromised, or cancer patients—all of which demand a lower threshold for imaging and expanded workup.

Next, the inpatient diagnostic strategy. Suspect stroke? Activate the stroke alert—determine last known well, check glucose, perform a focused neuro exam, and get emergent CT/MRI. For classic Bell’s palsy, routine labs and imaging aren’t required, but in hospitalized patients consider MRI with contrast or CSF if there are atypical features, infection risk, multiple cranial nerves involved, or no improvement by 3–6 weeks.

Treatment pearls you can use today:

We close with prognosis and counseling. Bell’s palsy has a 70–85% complete recovery rate (higher with early steroids), but 25–40% may have residual weakness or synkinesis—plan follow-up at 3 months if recovery lags. Stroke outcomes hinge on severity and speed to reperfusion, making rapid recognition critical.

Bottom line: Examine the forehead, hunt for red flags, image early when in doubt, protect the eye, treat fast, and never miss a stroke.